UID2362640
阅读权限120
专业分
贡献分
爱医币
鲜花
注册时间2010-7-4
|
马上注册,结交更多好友,享用更多功能,让你轻松玩转社区。
您需要 登录 才可以下载或查看,没有帐号?注册
x
以下是来自CIRCULATION的一片文献,2010年,
Abstract 1 of 8
Coronary Heart Disease
Acetaminophen Increases Blood Pressure in Patients With Coronary Artery Disease
Isabella Sudano, MD*; Andreas J. Flammer, MD*; Daniel Périat, MD; Frank Enseleit, MD; Matthias Hermann, MD; Mathias Wolfrum, MD; Astrid Hirt, RN; Priska Kaiser, RN; David Hurlimann, MD; Michel Neidhart, PhD; Steffen Gay, MD; Johannes Holzmeister, MD; Juerg Nussberger, MD; Pavani Mocharla, MSc; Ulf Landmesser, MD; Sarah R. Haile, PhD; Roberto Corti, MD; Paul M. Vanhoutte, MD; Thomas F. Lüscher, MD; Georg Noll, MD; Frank Ruschitzka, MD
From the Cardiovascular Center, Cardiology (I.S., A.J.F., D.P., F.E., M.H., M.W., A.H., P.K., D.H., J.H., U.L., R.C., T.F.L., G.N., F.R.), Department of Rheumatology (M.N.), and Cardiovascular Research, Institute of Physiology (P.M.), University Hospital Zurich, Zurich, Switzerland; Department of Internal Medicine, Division of Angiology and Hypertension, University Hospital Lausanne, Lausanne, Switzerland (J.N.); Institute for Social and Preventive Medicine, Biostatistics Unit (S.R.H.) and Center for Integrative Human Physiology (S.G., R.C., T.F.L., G.N., F.R.), University of Zurich, Zurich, Switzerland; and Department of Pharmacology and Pharmacy, University of Hong Kong, Hong Kong, China (P.M.V.).
Correspondence to Frank Ruschitzka, MD, FRCP (Edin), Cardiovascular Center Cardiology University Hospital Zurich, Rämistrasse 100, CH-8091 Zurich, Switzerland. E-mailfrank.ruschitzka@usz.ch
Background— Because traditional nonsteroidal antiinflammatory drugs are associated with increased risk for acute cardiovascular events, current guidelines recommend acetaminophen as the first-line **gesic of choice on the assumption of its greater cardiovascular safety. Data from randomized clinical trials prospectively addressing cardiovascular safety of acetaminophen, however, are still lacking, particularly in patients at increased cardiovascular risk. Hence, the aim of this study was to evaluate the safety of acetaminophen in patients with coronary artery disease.
Methods and Results— The 33 patients with coronary artery disease included in this randomized, double-blind, placebo-controlled, crossover study received acetaminophen (1 g TID) on top of standard cardiovascular therapy for 2 weeks. Ambulatory blood pressure, heart rate, endothelium-dependent and -independent vasodilatation, platelet function, endothelial progenitor cells, markers of the renin-angiotensin system, inflammation, and oxidative stress were determined at baseline and after each treatment period. Treatment with acetaminophen resulted in a significant increase in mean systolic (from 122.4±11.9 to 125.3±12.0 mm Hg P=0.02 versus placebo) and diastolic (from 73.2±6.9 to 75.4±7.9 mm Hg P=0.02 versus placebo) ambulatory blood pressures. On the other hand, heart rate, endothelial function, early endothelial progenitor cells, and platelet function did not change.
Conclusions— This study demonstrates for the first time that acetaminophen induces a significant increase in ambulatory blood pressure in patients with coronary artery disease. Thus, the use of acetaminophen should be evaluated as rigorously as traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors, particularly in patients at increased cardiovascular risk. |
1
展开
喜欢他/她就送朵鲜花吧,赠人玫瑰,手有余香!鲜花排行
- 懒洋羊+1感谢支持!感谢分享!
收到1朵
|